Success Metrics

Clinical Success Rate
100.0%

Based on 7 completed trials

Completion Rate
100%(7/7)
Active Trials
2(22%)
Results Posted
86%(6 trials)

Phase Distribution

Ph phase_1
1
11%
Ph not_applicable
1
11%
Ph early_phase_1
1
11%
Ph phase_4
3
33%
Ph phase_2
2
22%
Ph phase_3
1
11%

Phase Distribution

2

Early Stage

2

Mid Stage

4

Late Stage

Phase Distribution9 total trials
Early Phase 1First-in-human
1(11.1%)
Phase 1Safety & dosage
1(11.1%)
Phase 2Efficacy & side effects
2(22.2%)
Phase 3Large-scale testing
1(11.1%)
Phase 4Post-market surveillance
3(33.3%)
N/ANon-phased studies
1(11.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

100.0%

7 of 7 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(2)
Completed(7)

Detailed Status

Completed7
Active, not recruiting1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
100.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 11 (11.1%)
Phase 11 (11.1%)
Phase 22 (22.2%)
Phase 31 (11.1%)
Phase 43 (33.3%)
N/A1 (11.1%)

Trials by Status

active_not_recruiting111%
completed778%
recruiting111%

Recent Activity

Clinical Trials (9)

Drug Details

Intervention Type
DRUG
Total Trials
9